Pyrrothiogatain

Pyrrothiogatain is a transcription factor GATA3 inhibitor with an IC50 of 54.7 μM. Pyrrothiogatain inhibits the DNA-binding activity of GATA3 and inhibits the T helper 2 (Th2) cell differentiation and expression of Th2 cytokines. Pyrrothiogatain shows anti-infection effect by inhibiting ACE2 expression. Pyrrothiogatain can be used for the researches of inflammation, immunology, infection and cancer, such as colon cancer and SARS-CoV-2 infection[1][2][3][4].

Product Specifications

CAS Number

[477888-48-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Angiotensin-converting Enzyme (ACE) ; DNA/RNA Synthesis; Interleukin Related; SARS-CoV; TNF Receptor

Type

Reference compound

Related Pathways

Anti-infection; Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/pyrrothiogatain.html

Purity

98.61

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(C1=C(N2C(C)=CC=C2C)C=CS1)O

Molecular Formula

C11H11NO2S

Molecular Weight

221.28

Precautions

H302, H315, H319, H335

References & Citations

[1]Nomura S, et al. Pyrrothiogatain acts as an inhibitor of GATA family proteins and inhibits Th2 cell differentiation in vitro. Sci Rep. 2019 Nov 22;9 (1) :17335.|[2]Almuraikhy S, et al. Targeted Inhibition of GATA-3 by Pyrrothiogatain: Implications for Adipocyte Biology and Inflammatory Response. Cells. 2025 Jan 10;14 (2) :100.|[3]Israeli M, et al. Genome-wide CRISPR screens identify GATA6 as a proviral host factor for SARS-CoV-2 via modulation of ACE2. Nat Commun. 2022 Apr 25;13 (1) :2237.|[4]Kalim KW, et al. Targeting of Cdc42 GTPase in regulatory T cells unleashes antitumor T-cell immunity. J Immunother Cancer. 2022 Nov;10 (11) :e004806.